

TEST CHANGE – METHODOLOGY

Notification Date: September 11th, 2024

Effective Date: October 2, 2024

Test Names: Procainamide and N-Acetylprocainamide (NAPA), Serum or Plasma

Test ID: LAB33

Explanation: On the effective date, Procainamide and NAPA testing will move to new instrumentation, enabling faster turnaround times for inpatients experiencing life-threatening arrhythmias at VUH.

Note: There is approximately a 10% positive bias for NAPA results in the therapeutic range of 12-18 µg/mL.

Current Method – Vanderbilt Hospital Laboratory	New Method – Vanderbilt Hospital Laboratory
NAPA: Homogeneous Enzyme Immunoassay (ThermoScientific) Procainamide: Homogenous Enzyme Immunoassay (ThermoScientific)	NAPA: Homogeneous Enzyme Immunoassay (Roche) Procainamide: Homogeneous Enzyme Immunoassay (Roche)
Current Measurement Range	New Measurement Range
NAPA: 0.6 – 30 µg/mL Procainamide: 0.4 – 20 µg/mL	NAPA: 0.6 – 60 µg/mL Procainamide: 0.8 - 28 µg/mL

Questions: Please get in touch with Vanderbilt Medical Laboratories Customer Service at 615-875-5227 (5-LABS) or 800-551-5227 or visit our website: [Home | Vanderbilt Medical Laboratories \(vumc.org\)](https://www.vumc.org)